SUCRALFATE THERAPY OF PEPTIC-ULCER

Sucralfate made in Bulgaria (Farmaphim) and its Yugoslavian analogue venter have been tried in gastroduodenal ulcer. The drugs were given per os (1 g, 1 tablet) 4 times a day before meals for 20 days. Sucralfate treatment was assigned to 26 patients with gastric and 26 with duodenal ulcer. The other 20 gastric ulcer patients received venter. 10 patients with gastric and 20 with duodenal ulcer entered the control group receiving placebo. Attenuation of the symptoms was reported as early as on day 4 of the treatment in 85-100 % of the patients both with gastric and duodenal ulcer. The 20-day course of sucralfate treatment brought about a complete epithelization on gastric ulcer in 54 % while in venter treatment in 55 % of those treated versus placebo group 10 %. Duodenal ulcer epithelization occurred in sucralfate-treated group in 58 % against placebo group 17 %. The differences in treatment results between sucralfate and venter are immaterial, whereas against placebo they are significant (p < 0.05). Side effects were not serious.